Matt Sirovich And Jeremy Mindich

Neuroderm Ltd (NASDAQ:NDRM): Matt Sirovich And Jeremy Mindich’s Scopia Capital filed an amended 13D.

You can check out Scopia Capital’s latest holdings and filings here.

Please follow Scopia Capital (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Scopia Capital or update its stock holdings.

Matt Sirovich And Jeremy Mindich
Matt Sirovich And Jeremy Mindich
Scopia Capital

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Scopia Capital Management 0 205,358 0 205,358 205,358 0.78%
Scopia Management, Inc 0 205,358 0 205,358 205,358 0.78%
Matthew Sirovich 0 205,358 0 205,358 205,358 0.78%
Jeremy Mindich 0 205,358 0 205,358 205,358 0.78%
Matt Sirovich And Jeremy Mindich
Matt Sirovich And Jeremy Mindich
Scopia Capital

Page 1 of 11 – SEC Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934

(Amendment No. 4)*

NeuroDerm Ltd.
(Name of Issuer)
Ordinary Shares, par value NIS 0.01 per share
(Title of Class of Securities)
M74231107
(CUSIP Number)
August
31, 2017
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule
pursuant to which this Schedule is filed:

[X]      Rule
13d-1(b)

[_]      Rule
13d-1(c)

[_]      Rule
13d-1(d)

_________

(1) The remainder of this
cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The
information required in the remainder of this cover page shall not be deemed to be “filed’ for the purpose of Section
18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the
Act but shall be subject to all other provisions of the Act (however, see the Notes).

Follow Neuroderm Ltd.